Advertisement
Canada markets close in 2 hours 9 minutes
  • S&P/TSX

    22,220.22
    -126.54 (-0.57%)
     
  • S&P 500

    5,287.44
    -19.57 (-0.37%)
     
  • DOW

    39,178.20
    -492.84 (-1.24%)
     
  • CAD/USD

    0.7288
    -0.0018 (-0.25%)
     
  • CRUDE OIL

    76.68
    -0.89 (-1.15%)
     
  • Bitcoin CAD

    93,055.56
    -2,717.70 (-2.84%)
     
  • CMC Crypto 200

    1,475.07
    -27.59 (-1.84%)
     
  • GOLD FUTURES

    2,337.70
    -55.20 (-2.31%)
     
  • RUSSELL 2000

    2,060.75
    -20.96 (-1.01%)
     
  • 10-Yr Bond

    4.4810
    +0.0470 (+1.06%)
     
  • NASDAQ

    16,813.32
    +11.78 (+0.07%)
     
  • VOLATILITY

    12.32
    +0.03 (+0.24%)
     
  • FTSE

    8,339.23
    -31.10 (-0.37%)
     
  • NIKKEI 225

    39,103.22
    +486.12 (+1.26%)
     
  • CAD/EUR

    0.6736
    -0.0009 (-0.13%)
     

Revvity's (RVTY) Launch to Boost Pharma-Contract Partner Tie-Up

Revvity, Inc. RVTY recently announced that its software and informatics division, Revvity Signals, will launch Signals Synergy. Per the company, it is a software solution designed to drive greater collaboration, project management and data exchange between pharmaceutical and biotechnology sponsors with their external contract partners.

Revvity is expected to officially introduce Signals Synergy at the ongoing Bio-IT World Conference & Expo in Boston, MA.

The latest product is expected to significantly boost Revvity’s Signals Software portfolio and solidify its foothold in the niche space.

Significance of the Launch

Per Revvity, Signals Synergy is expected to expand its Signals Notebook and Signals Research Suite offerings to serve as a data steward and project management layer between sponsors and contract partners. These capabilities will likely enable Signals Synergy to streamline processes, enhance sustainability and reduce the errors and delays commonly associated with conventional systems. This will likely address the challenge of relying on email or file-sharing platforms to report complex scientific findings.

ADVERTISEMENT

Per management, Signals Synergy will likely merge scientific project management with efficient data sharing into one seamless platform.

Industry Prospects

Per a report by Transparency Market Research, the global healthcare informatics market was estimated at $35.6 billion in 2022 and is anticipated to reach $100.4 billion by 2031 at a CAGR of 12.6%. Factors like the increased automation in clinical laboratories and the growing adoption of electronic health records are expected to drive the market.

Given the market potential, the latest launch is expected to significantly boost Revvity’s global business.

Notable Launches

Last month, Revvity introduced the new Signals ChemDraw offering through its software and informatics division, Revvity Signals Software. The innovative chemistry suite is expected to transform the way researchers in the pharmaceutical and non-pharmaceutical chemical industries and academia develop and communicate complex chemical concepts and collaborate across disciplines.

The same month, Revvity introduced a flexible end-to-end workflow solution for newborn research. This will likely enable the users to utilize different instruments, reagents and databases based on a lab’s requirements.

In February, Revvity Signals unveiled the Signals Clinical solution. It is a software-as-a-service, end-to-end clinical data science platform designed to centralize all clinical trial data, providing fast, actionable insights for quicker clinical decisions and accelerated market delivery of therapeutics.

Price Performance

Shares of Revvity have lost 26.2% in the past year compared with the industry’s 2.2% decline. The S&P 500 has witnessed 22.6% growth in the said time frame.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Zacks Rank & Key Picks

Currently, Revvity carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, Cardinal Health, Inc. CAH and Cencora, Inc. COR.

DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 12.1%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 35.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

DaVita’s shares have gained 54.7% compared with the industry’s 12.4% rise in the past year.

Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.

Cardinal Health has gained 34.5% compared with the industry’s 4.5% rise in the past year.

Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 9.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.7%.

Cencora’s shares have rallied 42.1% against the industry’s 2.2% decline in the past year.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

DaVita Inc. (DVA) : Free Stock Analysis Report

Cardinal Health, Inc. (CAH) : Free Stock Analysis Report

Cencora, Inc. (COR) : Free Stock Analysis Report

Revvity Inc. (RVTY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research